Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16449769 | 0.89 | SIGMAR1 (0.38) | LMNATSHRSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL19601273 | 0.88 | POLB (0.39) | LMNATSHRSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL16449765 | 0.87 | SIGMAR1 (0.40) | LMNATSHRSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL25963873 | 0.84 | KDM1A (0.44) | LMNAKDM1ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL25963041 | 0.83 | POLB (0.50) | LMNATSHRSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL835434 | 0.81 | CYP19A1 (0.39) | LMNATSHRSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL16450881 | 0.80 | ACHE (0.38) | LMNAKDM1ASMN1; SMN2ADRA1DADRA1A | |
| SCHEMBL13318048 | 0.80 | CYP19A1 (0.46) | TSHRSMN1; SMN2POLBALDH1A1PKM | |
| SCHEMBL16675656 | 0.79 | MGLL (0.39) | LMNASMN1; SMN2POLBALDH1A1PKM | |
| SCHEMBL17190592 | 0.79 | ALDH1A1 (0.39) | SMN1; SMN2POLBALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745335-B2 | N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application | BLIRT S.A. (PL) | 2017-08-29 | — | — | US | disclosed |
| US-9745335-B2 | N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application | BLIRT S.A. (PL) | 2017-08-29 | — | — | US | disclosed |
| US-9447136-B2 | Semisynthetic derivatives of Nystatin A1 | BLIRT S.A. (PL) | 2016-09-20 | — | — | US | disclosed |
| US-20150291648-A1 | N-SUBSTITUTED SECOND GENERATION DERIVATIVES OF ANTIFUNGAL ANTIBIOTIC AMPHOTERICIN B AND METHODS OF THEIR PREPARATION AND APPLICATION | BLIRT S.A. (PL) | 2015-10-15 | — | — | US | disclosed |
| US-20150045316-A1 | SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1 | BLIRT S.A. (PL) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045316-A1 | SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1 | NPC1, NPC1L1, LSS | LMNA 1805/4885TSHR 3798/4885HSD17B10 3874/4885 |
| US-20150291648-A1 | N-SUBSTITUTED SECOND GENERATION DERIVATIVES OF ANTIFUNGAL ANTIBIOTIC AMPHOTERICIN B AND METHODS OF THEIR PREPARATION AND APPLICATION | ERG28, LSS, NPC1 | LMNA 741/4885TSHR 4423/4885HSD17B10 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.